MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Edwards’ latest-generation balloon-expandable transcatheter heart valve incorporates a proprietary calcification-resistant tissue technology
The medicine was well tolerated, with no unexpected safety issue
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
Subscribe To Our Newsletter & Stay Updated
